Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Voss

Showing results (281-290 of 419) with videos related to

Pageof 42
Sort By:
Nature Communications|August 22, 2020
A pan-cancer analysis of PBAF complex mutations and their association with immunotherapy responseA Ari Hakimi, Kyrollis Attalla, Renzo G DiNatale, et al.
European Urology|October 6, 2012
Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinomaA Ari Hakimi, Ying-Bei Chen, James Wren, et al.
Journal for Immunotherapy of Cancer|June 24, 2020
DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapyYasser Ged, Joshua L Chaim, Renzo G DiNatale, et al.
The Oncologist|June 23, 2025
Phase 1b/2 study of batiraxcept alone and in combination with cabozantinib with or without nivolumab for advanced clear cell renal cell carcinomaKathryn E Beckermann, Neil J Shah, Matthew T Campbell, et al.
European Journal of Cancer (Oxford, England : 1990)|May 11, 2019
Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitorsA Y Shah, R R Kotecha, E A Lemke, et al.
British Journal of Pharmacology|December 28, 2019
Cell-permeable high-affinity tracers for G<sub>q</sub> proteins provide structural insights, reveal distinct binding kinetics and identify small molecule inhibitorsMarkus Kuschak, Vigneshwaran Namasivayam, Muhammad Rafehi, et al.
Cancer|October 28, 2015
Validation and genomic interrogation of the MET variant rs11762213 as a predictor of adverse outcomes in clear cell renal cell carcinomaA Ari Hakimi, Irina Ostrovnaya, Anders Jacobsen, et al.
Urologic Oncology|November 15, 2017
Characterizing recurrent and lethal small renal masses in clear cell renal cell carcinoma using recurrent somatic mutationsBrandon J Manley, Ed Reznik, Mazyar Ghanaat, et al.
JCO Precision Oncology|September 11, 2020
Comprehensive Genomic Analysis of Metastatic Non-Clear-Cell Renal Cell Carcinoma to Identify Therapeutic TargetsMaria I Carlo, Nabeela Khan, Ahmet Zehir, et al.
European Urology|October 19, 2024
Corrigendum to "Cabozantinib Plus Nivolumab in Patients with Non-Clear Cell Renal Cell Carcinoma: Updated Results from a Phase II Trial" [Eur. Urol. 86(2) (2024) 90-94]Kelly N Fitzgerald, Chung-Han Lee, Martin H Voss, et al.
Pageof 42

Showing results (281-290 of 419) with videos related to

Sort By:
Pageof 42
Nature Communications|August 22, 2020
A pan-cancer analysis of PBAF complex mutations and their association with immunotherapy responseA Ari Hakimi, Kyrollis Attalla, Renzo G DiNatale, et al.
European Urology|October 6, 2012
Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinomaA Ari Hakimi, Ying-Bei Chen, James Wren, et al.
Journal for Immunotherapy of Cancer|June 24, 2020
DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapyYasser Ged, Joshua L Chaim, Renzo G DiNatale, et al.
The Oncologist|June 23, 2025
Phase 1b/2 study of batiraxcept alone and in combination with cabozantinib with or without nivolumab for advanced clear cell renal cell carcinomaKathryn E Beckermann, Neil J Shah, Matthew T Campbell, et al.
European Journal of Cancer (Oxford, England : 1990)|May 11, 2019
Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitorsA Y Shah, R R Kotecha, E A Lemke, et al.
British Journal of Pharmacology|December 28, 2019
Cell-permeable high-affinity tracers for G<sub>q</sub> proteins provide structural insights, reveal distinct binding kinetics and identify small molecule inhibitorsMarkus Kuschak, Vigneshwaran Namasivayam, Muhammad Rafehi, et al.
Cancer|October 28, 2015
Validation and genomic interrogation of the MET variant rs11762213 as a predictor of adverse outcomes in clear cell renal cell carcinomaA Ari Hakimi, Irina Ostrovnaya, Anders Jacobsen, et al.
Urologic Oncology|November 15, 2017
Characterizing recurrent and lethal small renal masses in clear cell renal cell carcinoma using recurrent somatic mutationsBrandon J Manley, Ed Reznik, Mazyar Ghanaat, et al.
JCO Precision Oncology|September 11, 2020
Comprehensive Genomic Analysis of Metastatic Non-Clear-Cell Renal Cell Carcinoma to Identify Therapeutic TargetsMaria I Carlo, Nabeela Khan, Ahmet Zehir, et al.
European Urology|October 19, 2024
Corrigendum to "Cabozantinib Plus Nivolumab in Patients with Non-Clear Cell Renal Cell Carcinoma: Updated Results from a Phase II Trial" [Eur. Urol. 86(2) (2024) 90-94]Kelly N Fitzgerald, Chung-Han Lee, Martin H Voss, et al.
Pageof 42